جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.
RA

Raghad Alsharif

بانتظار توثيق الانتساب2025–2026
4وثائق Scopus
14استشهاداً
2مؤشر h
0منها بانتماء الجامعة
إجمالي Scopus (كل الجهات)
مراجعةوصول مفتوح20269استشهاد· Semantic Scholar

Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies

Frontiers in Immunology · مجلد 16 · 1690464-1690464

Gliomas, and particularly glioblastoma (GBM), remain among the most lethal primary brain tumors, with outcomes constrained by extensive intra tumor heterogeneity, a profoundly immunosuppressive tumor microenvironment (TME), and the restrictive nature of the blood-brain barrier (BBB). Although immunotherapies, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) T and NK cells, and oncolytic virotherapy, have redefined treatment paradigms in other malignancies, their efficacy in gliomas has been modest, limited by low tumor mutational burden, antigenic plasticity, metabolic suppression, and therapy-associated immunosuppression. Recent advances in multi-antigen targeting, metabolic reprogramming, and innovative delivery strategies have enhanced preclinical efficacy, while the integration of emerging biomarkers such as ADAMTSL4, ACSS3, and radiomics-derived immune signatures offers opportunities for precision patient stratification. Converging developments in real-time molecular monitoring, spatial immunoprofiling, and rationally designed combination regimens hold the potential to recalibrate the glioma immune landscape, paving the way toward clinically impactful and durable immunotherapeutic responses.

glioma immunotherapyglioblastomaimmunosuppressive tumor microenvironmentblood-brain barrier
مراجعةمفتوح (مستودع)2026

Patient‐Derived Organoids in Functional Precision Oncology: Tumor Modeling, Drug‐Response Prediction, and Clinical Translation

Cell Biochemistry and Function · مجلد 44 (10) · e70321-e70321

Patient-derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long-standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three-dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic characteristics of their tumors of origin, enabling more accurate modeling of tumor heterogeneity and disease evolution. Over the last decade, rapid methodological advances in organoid culture systems, extracellular matrices (ECMs), and growth factor optimization have facilitated the establishment of organoid models for a wide range of malignancies and the development of large living biobanks representing diverse patient populations. These models are increasingly being utilized to study cancer biology, elucidate mechanisms of treatment resistance, and evaluate patient-specific therapeutic responses, highlighting their potential as tools for precision oncology. However, important challenges remain, including incomplete representation of the tumor microenvironment (TME), variability in culture conditions, and limited scalability, and the need for greater standardization and validation. Consequently, although PDOs show considerable promise for translational research and personalized medicine, their routine clinical implementation remains largely investigational, and their clinical utility has not yet been fully established. This review examines the technological foundations of PDO generation, assesses their role as experimental models of tumor biology, and discusses their expanding applications in translational cancer research and precision oncology while highlighting key challenges that must be addressed before their widespread clinical adoption.

patient-derived organoidsprecision oncologytumor heterogeneitydrug response prediction
مقالوصول مفتوح2026

Flexor Tendon Sheath Ganglion Causing Concurrent Trigger Wrist and Carpal Tunnel Syndrome

Case Reports in Orthopedics · مجلد 2026 (1) · 8963799-8963799

Introduction: Trigger wrist is a rare condition often misdiagnosed as trigger finger or carpal tunnel syndrome (CTS). It is characterized by painful clicking, snapping, or locking of the wrist during movement and can result from space-occupying lesions, such as ganglion cysts. This case highlights an unusual presentation of trigger wrist associated with CTS caused by a ganglion cyst in the flexor tendon sheath. Case Presentation: A 44-year-old male presented with paresthesia, severe pain, and triggering of the right wrist. Imaging and histopathology confirmed a ganglion cyst between the flexor digitorum profundus tendons of the index and middle fingers, compressing the median nerve and causing CTS. Surgical excision via a carpal tunnel approach resulted in complete symptom resolution. Conclusion: This case emphasizes the diagnostic challenges of trigger wrist and the importance of considering it in patients with CTS-like symptoms and mechanical wrist dysfunction. Ganglion cysts in flexor tendon sheaths are rare, and surgical excision remains an effective treatment. Increased awareness and reporting of such cases can improve clinical recognition and management.

ganglion cystflexor tendon sheathcarpal tunnel syndromemedian nerve compression
مراجعةوصول مفتوح20255استشهاد· Semantic Scholar

Linking epigenetic mechanisms of T cell dysfunction with pathophysiology of type 1 diabetes mellitus

Frontiers in Immunology · مجلد 16 · 1664255-1664255

β-cell destruction by autoreactive T cells is a hey hallmark of type 1 diabetes mellitus (T1D). Epigenetic mechanisms-including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs-play critical roles in regulating T-cell development, activation, and tolerance. Disruption of these processes contributes to immune imbalance and the onset of T1D. This review summarizes current insights into how epigenetic regulation shapes T-cell function and highlights emerging evidence linking these changes to environmental influences such as gut microbiota, diet, and viral infections. Exploring the interaction between genetic susceptibility and environmental triggers through an epigenetic framework not only advances our understanding of T1D pathogenesis but also provides opportunities for biomarker discovery and the development of targeted epigenetic therapies. With further research, these advances hold promise for improving precision medicine strategies in T1D.

type 1 diabetesT cell dysfunctionepigenetic regulationDNA methylation